bortezomib is a medication owned by Fresenius Kabi Usa. It was first allowed on the market on November 6, 2017. It contains the active ingredient bortezomib and is available in powder for intravenous use. Fresenius Kabi Usa holds 1 patent for bortezomib.
The patent for Bortezomib is set to expire on November 3, 2032. This means that generics of Bortezomib might possibly be available after this date, unless a Paragraph IV patent challenge occurs that could potentially make Bortezomib generic available earlier.
bortezomib is primarily used in the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting the activity of proteasomes, thereby preventing cancer cells from breaking down unwanted proteins, leading to cell death.
At present, there are 1 recorded patent for Bortezomib, owned by Fresenius Kabi Usa. This patent, US8962572 titled 'Bortezomib formulations', is set to expire on November 3, 2032. This protects the Bortezomib alone, allowing for a potential generic version after this date. However, the availability of a generic Bortezomib could potentially be sooner if a Paragraph IV patent challenge occurs. Below are the details of the patent: